

Levent Mehmet AentÃ¼rk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9344595/publications.pdf>

Version: 2024-02-01

50
papers

2,141
citations

218381

26
h-index

223531

46
g-index

50
all docs

50
docs citations

50
times ranked

2368
citing authors

#	ARTICLE	IF	CITATIONS
1	Current management of pelvic organ prolapse in aging women: EMAS clinical guide. <i>Maturitas</i> , 2018, 110, 118-123.	1.0	21
2	Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide. <i>Maturitas</i> , 2018, 107, 7-12.	1.0	88
3	The sexual health approach in postmenopause: The five-minutes study. <i>Maturitas</i> , 2018, 108, 31-36.	1.0	17
4	Menopause and diabetes: EMAS clinical guide. <i>Maturitas</i> , 2018, 117, 6-10.	1.0	91
5	Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. <i>Maturitas</i> , 2017, 101, 23-30.	1.0	94
6	Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.. <i>Maturitas</i> , 2017, 102, 76-77.	1.0	0
7	Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Position Statement. <i>Maturitas</i> , 2017, 100, 86-91.	1.0	16
8	Osteoporosis management in patients with breast cancer: EMAS position statement. <i>Maturitas</i> , 2017, 95, 65-71.	1.0	42
9	Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). <i>Maturitas</i> , 2016, 89, 63-72.	1.0	67
10	A model of care for healthy menopause and ageing: EMAS position statement. <i>Maturitas</i> , 2016, 92, 1-6.	1.0	23
11	EMAS recommendations for conditions in the workplace for menopausal women. <i>Maturitas</i> , 2016, 85, 79-81.	1.0	40
12	EMAS position statement: Testosterone replacement therapy in the aging male. <i>Maturitas</i> , 2016, 84, 94-99.	1.0	53
13	Adenomyosis: What is New?. <i>Women's Health</i> , 2015, 11, 717-724.	0.7	23
14	Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. <i>Journal of Assisted Reproduction and Genetics</i> , 2014, 31, 213-220.	1.2	47
15	Serum AMH levels in the differential diagnosis of hyperandrogenemic conditions. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 177, 121-125.	0.5	10
16	Serum Anti-Müllerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles. <i>Journal of Assisted Reproduction and Genetics</i> , 2012, 29, 589-595.	1.2	20
17	Serum anti-Müllerian hormone concentrations in reproductive age women with and without polycystic ovary syndrome: the influence of body mass index. <i>Reproductive Medicine and Biology</i> , 2011, 10, 113-120.	1.0	12
18	The impact of body mass index on assisted reproduction. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 228-235.	0.9	77

#	ARTICLE	IF	CITATIONS
19	Thin endometrium in assisted reproductive technology. <i>Current Opinion in Obstetrics and Gynecology</i> , 2008, 20, 221-228.	0.9	111
20	Expression of Proliferative and Preapoptotic Molecules in Human Myometrium and Leiomyoma Throughout the Menstrual Cycle. <i>Reproductive Sciences</i> , 2007, 14, 678-686.	1.1	12
21	The effect of tibolone versus 17 β -estradiol on climacteric symptoms in women with surgical menopause: A randomized, cross-over study. <i>Maturitas</i> , 2007, 56, 61-68.	1.0	21
22	Tibolone and breast cancer. <i>Postgraduate Medical Journal</i> , 2006, 82, 658-662.	0.9	9
23	Is laparoscopy necessary before assisted reproductive technology?. <i>Current Opinion in Obstetrics and Gynecology</i> , 2005, 17, 243-248.	0.9	14
24	High rate of aneuploidy in luteinized granulosa cells obtained from follicular fluid in women who underwent controlled ovarian hyperstimulation. <i>Fertility and Sterility</i> , 2005, 84, 802-804.	0.5	18
25	Is endometrial apoptosis evidence of endometrial aging in unexplained infertility? a preliminary report. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2005, 121, 195-201.	0.5	8
26	Is serum leptin level regulated by thyroid functions ,lipid metabolism and insulin resistance in polycystic ovary syndrome?. <i>Gynecological Endocrinology</i> , 2003, 17, 223-229.	0.7	14
27	Chemokine Receptor Expression in Human Endometrium1. <i>Biology of Reproduction</i> , 2003, 68, 1491-1495.	1.2	36
28	Expression of pre-apoptotic and proliferative molecules in human myometrium and leiomyomata throughout the menstrual cycle. <i>Fertility and Sterility</i> , 2002, 78, S109-S110.	0.5	1
29	Leptin receptor variant in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2002, 78, 1334-1335.	0.5	8
30	Expression of aminopeptidase N in human endometrium and regulation of its activity by estrogen. <i>Fertility and Sterility</i> , 2001, 75, 1172-1176.	0.5	28
31	Effect of gonadotropin-releasing hormone agonists on monocyte chemotactic protein-1 production and macrophage infiltration in leiomyomatous uterus. <i>Fertility and Sterility</i> , 2001, 76, 792-796.	0.5	13
32	Interleukin-8 in the Human Fallopian Tube. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2660-2667.	1.8	50
33	Interleukin 8 production and interleukin 8 receptor expression in human myometrium and leiomyoma. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 184, 559-566.	0.7	45
34	Monocyte chemotactic protein-1 expression in human corpus luteum. <i>Molecular Human Reproduction</i> , 1999, 5, 697-702.	1.3	47
35	Changes in bone mineral density with age, menopausal status and body mass index in Turkish women. <i>Climacteric</i> , 1999, 2, 45-51.	1.1	19
36	Regulation of Monocyte Chemotactic Protein-1 Expression in Human Endometrial Stromal Cells by Estrogen and Progesterone1. <i>Biology of Reproduction</i> , 1999, 61, 85-90.	1.2	84

#	ARTICLE	IF	CITATIONS
37	Morphometric assessment of mature and diminished-maturity human spermatozoa: sperm regions that reflect differences in maturity*. Human Reproduction, 1999, 14, 2007-2014.	0.4	68
38	Immunology of endometriosis. Journal of Reproductive Immunology, 1999, 43, 67-83.	0.8	45
39	Leukemia Inhibitory Factor in Human Reproduction. American Journal of Reproductive Immunology, 1998, 39, 144-151.	1.2	77
40	The Peritoneal Fluid Levels of Interleukin-12 in Women with Endometriosis. American Journal of Reproductive Immunology, 1998, 39, 152-156.	1.2	23
41	The effect of monocyte chemotactic protein 1 in intraperitoneal adhesion formation in a mouse model. American Journal of Obstetrics and Gynecology, 1998, 179, 438-443.	0.7	22
42	Adrenal androgenic response to 2-hour ACTH stimulation test in women with PCOS. Gynecological Endocrinology, 1998, 12, 223-229.	0.7	7
43	Basic Fibroblast Growth Factor: Peritoneal and Follicular Fluid Levels and its Effect on Early Embryonic Development. Fertility and Sterility, 1998, 69, 1145-1148.	0.5	43
44	Interleukin-8 Induces Proliferation of Endometrial Stromal Cells: a Potential Autocrine Growth Factor1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1201-1205.	1.8	134
45	Interleukin-8 in the Human Endometrium¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1783-1787.	1.8	130
46	Follicular fluid of women with endometriosis stimulates the proliferation of endometrial stromal cells. Human Reproduction, 1998, 13, 3492-3495.	0.4	33
47	The role of monocyte chemotactic protein-1 in intraperitoneal adhesion formation. Human Reproduction, 1998, 13, 1194-1199.	0.4	47
48	Interleukin-8 Induces Proliferation of Endometrial Stromal Cells: a Potential Autocrine Growth Factor. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1201-1205.	1.8	107
49	Interleukin-8 in the Human Endometrium. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1783-1787.	1.8	107
50	Mammographic changes in women on hormonal replacement therapy. Maturitas, 1996, 25, 51-57.	1.0	19